Tumori Journal Abstract Book - October 2020 - 154

154	

Tumori Journal 106(2S)

was correlated to the clinical response and survival. In specific, exploratory univariate logistic regression revealed
that both higher DEos at T2-T0 and DEos at T1-T0 were
significantly associated with better disease control rate (p
<0.05 and p =0.078, respectively). In addition, log-rank
test performed on both DEos at T2-T0 and DEos at T1-T0
revealed that higher variation during treatment was correlated with improvement in terms of OS (p-value <0.01),
identifying only DEos at T1-T0 as a positive prognostic
factor of survival.
Conclusions: Our data suggest that anti-PD1 mAbs can
influence Eos count and its increase appears to be a potential biomarker associated with immunotherapy benefit and
better OS, thus offering eosinophilia as a peripheral, readily available biomarker of response to immunotherapy.
Anyway, further large studies are needed.

found that both ECOG (0-1 vs 2) and previous RT (No vs
Yes) statistically impacted on DCR after 2 months
(p=0.0180 and 0.0471, respectively) and 3 months (p=
0.0145, p= 0.0067, respectively) of treatment. Concerning
the safety profile, 8 pts (61.5%) experienced adverse
events (AEs). Grade 3-4 AEs occurred in 1 (7.7%) pt
(Myasthenia), which leads to therapy suspension. The
most common AEs were pruritus (38.5%), asthenia
(30.8%), constipation (23.1%), diarrhea (15.4%).
Conclusions: In our experience Cemiplimab confirmed an
high antitumoral activity with a good safety profile in
advanced cSCCs. We highlighted that pts with ECOG PS
0-1 and without previous RT treatment seem to benefit
most from Cemiplimab. A larger sample of pts and a longer
follow up will provide us more detailed data about efficacy
and safety of this new drug.

M03

M04

Cemiplimab in advanced Cutaneous
Squamous Cell Carcinoma:
preliminary data from a single
institution

Immunotherapy in Metastatic
Uveal Melanoma: a Italian singlecenter experience

Greco S.1, Rimini M.1, Riggi M.L.1, Pipitone S.1, Pugliese G.1, Dominici
M.1, Depenni R.1
1

Azienda Ospedaliero Universitaria Policlinico di Modena, Modena

Background: Advanced cutaneous squamous cell carcinoma (aCSCC), which include both metastatic disease
(mCSCC) and locally advanced (laCSCC) disease not suitable to curative RT or surgery, have an unfavorable prognosis with scarce therapeutic options. Cemiplimab is an
anti-PD1 human antibody with positive results in Phase I/
II studies in aCSCC that lead to EMA approval on June
2019. Here wepresent our preliminary data.
Matherial and Methods: Prospective analysis of medical
records of patients (pts) with aCSCC treated with
Cemiplimab from July 2019 to May 2020 at Modena
Cancer Center were conducted. Clinical parameters
deemed of interest were collected. Disease Control Rate
(DCR) at 2 and 3 months of treatment were evaluated by
logistic regression analysis.
Results: During the study period, 13 pts aged 50 to 95
years (Median age 86 years) and with aCSCC were treated
with Cemiplimab. ECOG Performance Status (PS) was
0-1 in 9 pts (69.2%) and 2 in 4 pts (30.8%). Median OS
and PFS has not yet been reached at the cut off time of
analysis (May 19, 2020). Up to now 8 pts are still on treatment; in these pts Median Duration of response was 3.45
months (0.7-12.1 months). An objective response was
observed in 8 (61.5%) of 13 pts. The best overall response
was: 4 (30.8%) pts with a complete response and 4 (30.8%)
with a partial response. DCR was obtained in 10 pts
(76.9%). By performinglogistic regression analysis,we

Defferrari C.1, Clavarezza M.2, D'Amico M.2, Gozza A.2, Provinciali
N.2, Rutigliani M.2, Corradengo D.3, Rossi U.3, Bacigalupo L.2,
Banderali S.2, Mosci C.2
1
ospedale Galliera, Genova; 2E.O. Ospedale Galliera, Genova; 3Ospedale San
Martino, Genova

Background: Metastatic Uveal Melanoma (MUM) is an
aggressive neoplasm with limited treatment options and
poor prognosis. Despite the excellent immunotherapy
response in cutaneous melanoma, anedoctal studies have
shown very low response rates were shown in Uveal
Melanoma. However, current guidelines on Cutaneous
Melanoma and Uveal Melanoma are the same. We collected data from 10 MUM patients treated with pembrolizumab in our Hospital.
Material and Methods: A total of ten patients with MUM
were treated with Pembrolizumab 200 mg (flat dose) as
first line therapy from February 2018 to March 2020 for
metastatic disease. All the patients had hepatic disease
localizations, one patient had lung lesions also. At baseline
all patients underwent liver biopsy, BRAF and PDL1 analysis, abdomen resonance (RM), total body CT scan (CT
scan) which were repeated every 3 cycles.
Results: The mean age was 66 +SD years. The median
time lapse from the first diagnosis of Uveal Melanoma to
the onset of metastasis was 5 years (range 0.5-17 years).
The median largest baseline metastatic hepatic lesion was
59 mm (range 22 to 100 mm).
All patients were BRAF and PDL1 negative and performed
Pembrolizumab as first line therapy. Only one patient, with
lowest tumoral burden, had stable disease after 3 cycles
and low progression disease subsequently. The other nine
Tumori Journal Abstract Book - October 2020

Table of Contents for the Digital Edition of Tumori Journal Abstract Book - October 2020
